CULTURED AFB ANTI TUBERCULAR DST, RAPID 10 DRUGS PANEL (SECOND LINE)
MRP - ₹ 11,300
What is a CULTURED AFB ANTI TUBERCULAR DST, RAPID 10 DRUGS PANEL (SECOND LINE)?
The Cultured AFB Antitubercular DST, Rapid 10 Drugs Panel (Second Line) is a specialized culture-based test used to evaluate drug resistance in Mycobacterium tuberculosis isolates. It determines susceptibility to ten second-line antitubercular drugs, which are critical for managing multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. This test is performed to guide clinicians in tailoring effective treatment regimens, prevent ineffective therapy, and support public health efforts in controlling resistant TB strains through accurate and timely drug resistance profiling.
Additional Information
| Also known as/ Other names: | Second-Line DST for M. tuberculosis, Rapid 10-Drug Second-Line TB, Susceptibility Panel, AFB Second-Line DST, 10-Drug Panel, M. tuberculosis Rapid DST – Second-Line Agents |
| Parameters: | 10 |
| Recommended for: | M/F/Others |
| Sample Type: | Submit pure M. tuberculosis complex growth in sterile sealed container |
| Patient Preparation: | No prior preparation is needed |
| Reports: | 22 Days |
FAQs
It is crucial for patients suspected of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis to guide effective treatment.
Patients with TB not responding to first-line drugs or those with suspected drug resistance should undergo this test.
It detects drug resistance in TB bacteria against second-line antitubercular medications.
Yes, it provides definitive evidence of resistance to specific second-line drugs.
No, this test is diagnostic for infection resistance, not hereditary risk.
It guides drug selection but does not guarantee treatment success, which depends on patient response and adherence.
Yes, if drug-resistant TB is suspected, cultures from pediatric patients can be tested.